Koch Institute Symposium on Cancer Immunology and Immunotherapy

The 12th annual summer symposium of The Koch Institute for Integrative Cancer Research at MIT was held in Cambridge, Massachusetts, on June 14, 2013. The symposium, entitled “Cancer Immunology and Immunotherapy,” focused on recent advances in preclinical research in basic immunology and biomedical engineering and their clinical application in cancer therapies. The day-long gathering also provided a forum for discussion and potential collaborations between engineers and clinical investigators. The major topics presented included (i) enhancement of adoptive cell therapy by engineering to improve the ability and functionality of T cells against tumor cells; (ii) current therapies using protein and antibody therapeutics to modulate endogenous antitumor immunity; and (iii) new technologies to identify molecular targets and assess therapeutic efficacy, and devices to control and target drug delivery more effectively and efficiently. Cancer Immunol Res; 1(4); 217–22. ©2013 AACR.

[1]  D. Irvine,et al.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. , 2012, Biomaterials.

[2]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[3]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[4]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[5]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[6]  D. Mooney,et al.  Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines , 2011, Biomatter.

[7]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[8]  J Christopher Love,et al.  Massively parallel detection of gene expression in single cells using subnanolitre wells. , 2010, Lab on a chip.

[9]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[10]  D. Greiner,et al.  Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.

[11]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[12]  Maria F. Fragoso,et al.  Human CD34+ CD133+ Hematopoietic Stem Cells Cultured with Growth Factors Including Angptl5 Efficiently Engraft Adult NOD-SCID Il2rγ−/− (NSG) Mice , 2011, PloS one.

[13]  S. Rosenberg,et al.  T-cell therapy at the threshold , 2012, Nature Biotechnology.

[14]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[15]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[16]  J Christopher Love,et al.  Multidimensional analysis of the frequencies and rates of cytokine secretion from single cells by quantitative microengraving. , 2010, Lab on a chip.

[17]  Jianzhu Chen,et al.  Human Fetal Hepatic Progenitor Cells Are Distinct from, but Closely Related to, Hematopoietic Stem/Progenitor Cells , 2013, Stem cells.

[18]  M. Hemann,et al.  Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies , 2012, Oncogene.

[19]  Darrell J Irvine,et al.  In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[20]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[21]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[22]  J Christopher Love,et al.  Single-cell analysis of the dynamics and functional outcomes of interactions between human natural killer cells and target cells. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[23]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[24]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[25]  M. Sznol,et al.  Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy , 2011, The Yale journal of biology and medicine.

[26]  I. Frazer,et al.  Development of therapeutic HPV vaccines. , 2009, The Lancet. Oncology.

[27]  Jianzhu Chen,et al.  Engineering humanized mice for improved hematopoietic reconstitution , 2012, Cellular and Molecular Immunology.

[28]  D. Pardoll,et al.  A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 , 2009, Clinical Cancer Research.

[29]  J Christopher Love,et al.  Development and optimization of a process for automated recovery of single cells identified by microengraving , 2010, Biotechnology progress.

[30]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[31]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[32]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[33]  Nikolaus Rajewsky,et al.  Modeling the Initiation and Progression of Human Acute Leukemia in Mice , 2022 .

[34]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[35]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[36]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[37]  R. Clark,et al.  Human Papillomavirus 16-Associated Cervical Intraepithelial Neoplasia in Humans Excludes CD8 T Cells from Dysplastic Epithelium , 2010, The Journal of Immunology.

[38]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[39]  Douglas A. Lauffenburger,et al.  Polyfunctional responses by human T cells result from sequential release of cytokines , 2011, Proceedings of the National Academy of Sciences.

[40]  J. C. Love,et al.  A microengraving method for rapid selection of single cells producing antigen-specific antibodies , 2006, Nature Biotechnology.

[41]  C. Rice,et al.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. , 2011, Gastroenterology.

[42]  B. Levine,et al.  Perspective: Assembly line immunotherapy , 2013, Nature.

[43]  M. Bility,et al.  Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis , 2012, Nature Protocols.

[44]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[45]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.